Clinical Trials Browser

Phase 2 × NIH × aldesleukin × Clear all

NCT03412877 2026-03-17

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Phase 2 Recruiting

BreastEndocrineGynecologicNETPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT01174121 2026-03-04

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Phase 2 Recruiting

BreastGastrointestinalGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05155033 2026-02-17

Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma

Phase 2 Recruiting

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT01319565 2025-12-19

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

Phase 2 Completed

102 enrolled 12 charts

Melanoma, Skin Neoplasms

NCT02621021 2025-11-21

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

Phase 2 Recruiting

Melanoma, Skin Neoplasms

NCT06690281 2025-09-11

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

Phase 2 Withdrawn

Gastrointestinal

Duodenal Neoplasms, Liver Neoplasms, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04102436 2024-03-12

Non-Viral TCR Gene Therapy

Phase 2 Withdrawn

BreastGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Urogenital Neoplasms

NCT01993719 2023-01-18

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Phase 2 Completed

33 enrolled 21 charts

Melanoma

NCT01967823 2021-03-24

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

Phase 2 Completed

11 enrolled 12 charts

BreastCNSDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Meningioma, Neoplasm Metastasis

NCT04536922 2021-02-01

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

Phase 2 Withdrawn

Gastrointestinal

Metastatic HPV-16 Positive Squamous Cell Anal Cancer

NCT01369875 2019-12-10

Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma

Phase 2 Terminated

2 enrolled 8 charts

Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT00670748 2019-11-19

Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer

Phase 2 Terminated

45 enrolled 15 charts

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis

NCT01258855 2019-05-10

Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Phase 2 Completed

84 enrolled 13 charts

Melanoma

NCT01585428 2018-03-07

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers

Phase 2 Completed

29 enrolled 12 charts

GastrointestinalGenitourinaryGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms, Papillomavirus Infections

NCT00001827 2017-10-06

p53 Vaccine for Ovarian Cancer

Phase 2 Terminated

Neoplasms, Ovarian Neoplasms

NCT02111863 2017-09-19

Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Phase 2 Terminated

6 enrolled 9 charts

Melanoma, Skin Neoplasms

NCT00089778 2017-08-01

Vaccine Treatment of Kidney Cancer

Phase 2 Terminated

11 enrolled 12 charts

Kidney Neoplasms

NCT01271907 2017-08-01

Drosophila-generated CTL

Phase 2 Terminated

3 enrolled 8 charts

Melanoma, Neoplasms, Skin Neoplasms

NCT02062359 2016-06-24

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma

Phase 2 Terminated

2 enrolled 7 charts

Melanoma, Neoplasm Metastasis

NCT00096382 2015-10-28

Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2 Completed

34 enrolled 11 charts

Melanoma

NCT00610311 2015-10-28

Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma

Phase 2 Terminated

3 enrolled 10 charts

Melanoma, Skin Neoplasms

NCT00704938 2015-10-28

Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer

Phase 2 Terminated

3 enrolled 8 charts

DermatologicGenitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma

NCT00706992 2015-10-28

Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients

Phase 2 Terminated

50 enrolled 13 charts

Melanoma

NCT00923195 2015-10-28

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

Phase 2 Completed

4 enrolled 11 charts

Melanoma, Skin Neoplasms

NCT00665470 2015-10-19

Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma

Phase 2 Completed

10 enrolled 9 charts

Melanoma, Skin Neoplasms

NCT01495572 2015-10-15

Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells

Phase 2 Terminated

5 enrolled 9 charts

Melanoma, Skin Neoplasms

NCT01118091 2015-10-08

Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...

Phase 2 Completed

12 enrolled 10 charts

Melanoma, Skin Neoplasms

NCT00126490 2015-06-30

Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Phase 2 Completed

19 enrolled 9 charts

Carcinoma, Renal Cell

NCT00002846 2013-12-19

Interleukin-2 in Treating Patients With Metastatic or Recurrent Kidney Cancer

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00002847 2013-12-19

Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00080977 2013-12-19

High-Dose Intravenous Interleukin-2 in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer) That Has Not Responded to Previous Low-Dose Intravenous or Subcutaneous Interleukin-2

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00002589 2013-12-18

Lymphocyte Therapy in Treating Patients With Kidney Cancer

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00003181 2013-12-04

Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00003090 2013-11-06

Biological Therapy in Previously Treated Patients With Non-small Cell Lung Cancer

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00003604 2013-11-06

Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer That Has Been Removed With Surgery

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00003664 2013-11-06

Combination Chemotherapy and Biological Therapy In Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed Surgically

Phase 2 Unknown

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00006228 2013-10-08

Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms, Breast Neoplasms, Male

NCT00003743 2013-09-17

Interleukin-2 in Treating Children With Stage IV Neuroblastoma Who Have Received Induction Therapy and Peripheral Stem Cell Transplantation

Phase 2 Unknown

Neuroblastoma

NCT00059904 2013-07-18

Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin's Lymphoma

Phase 2 Completed

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse

NCT00002535 2013-06-26

Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma

Phase 2 Completed

Melanoma

NCT00003568 2013-06-26

Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT00019331 2013-06-20

Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors

Phase 2 Completed

CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Testicular Germ Cell Tumor, Squamous Cell Carcinoma of Head and Neck, Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Lung Neoplasms, Melanoma, Pancreatic Neoplasms, Salivary Gland Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

NCT00019383 2013-06-20

Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT00019487 2013-06-20

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT00019669 2013-06-20

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT00019721 2013-06-20

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT00019734 2013-06-20

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT00019994 2013-06-19

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Phase 2 Completed

Melanoma

NCT00020358 2013-06-19

Vaccine Therapy in Treating Patients With Melanoma

Phase 2 Completed

Melanoma

NCT00020397 2013-06-19

Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma

Phase 2 Completed

Melanoma